Charles River Laboratories Intl. (NYSE:CRL) had its price target cut by investment analysts at Barclays from $170.00 to $154.00 in a research report issued on Thursday, BenzingaRatingsTable reports. The brokerage presently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price suggests a potential upside of 22.30% from the stock’s current price.

A number of other equities research analysts have also weighed in on the stock. Robert W. Baird reissued an “outperform” rating and set a $185.00 price objective (up from $165.00) on shares of Charles River Laboratories Intl. in a report on Wednesday, February 12th. KeyCorp boosted their price objective on shares of Charles River Laboratories Intl. from $151.00 to $162.00 and gave the company an “overweight” rating in a report on Monday, December 9th. Wells Fargo & Co assumed coverage on shares of Charles River Laboratories Intl. in a report on Tuesday, January 7th. They set an “overweight” rating and a $180.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of Charles River Laboratories Intl. from $156.00 to $176.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Finally, Jefferies Financial Group decreased their target price on shares of Charles River Laboratories Intl. from $200.00 to $139.00 and set a “buy” rating for the company in a research report on Monday. Six research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $167.67.

NYSE CRL traded up $6.57 on Thursday, hitting $125.92. The stock had a trading volume of 16,399 shares, compared to its average volume of 652,359. The business’s fifty day moving average price is $149.24 and its 200 day moving average price is $144.08. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.44 and a quick ratio of 1.21. Charles River Laboratories Intl. has a 52-week low of $95.58 and a 52-week high of $179.38. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of 24.87, a price-to-earnings-growth ratio of 1.06 and a beta of 1.04.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.83 by $0.18. The business had revenue of $691.10 million for the quarter, compared to analyst estimates of $685.46 million. Charles River Laboratories Intl. had a net margin of 9.61% and a return on equity of 22.17%. The business’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.49 earnings per share. As a group, sell-side analysts anticipate that Charles River Laboratories Intl. will post 7.39 EPS for the current year.

In related news, CEO James C. Foster sold 44,303 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $166.70, for a total transaction of $7,385,310.10. Following the completion of the transaction, the chief executive officer now owns 313,054 shares in the company, valued at approximately $52,186,101.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO David Ross Smith sold 8,211 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $166.72, for a total transaction of $1,368,937.92. Following the transaction, the chief financial officer now owns 25,219 shares of the company’s stock, valued at approximately $4,204,511.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,085 shares of company stock valued at $11,930,124. Insiders own 1.80% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. acquired a new position in shares of Charles River Laboratories Intl. during the 4th quarter worth about $34,000. Valeo Financial Advisors LLC grew its stake in Charles River Laboratories Intl. by 239.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 241 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 170 shares in the last quarter. CNB Bank purchased a new stake in Charles River Laboratories Intl. during the 4th quarter valued at about $41,000. Chevy Chase Trust Holdings Inc. purchased a new stake in Charles River Laboratories Intl. during the 4th quarter valued at about $91,000. Finally, Exchange Traded Concepts LLC purchased a new stake in Charles River Laboratories Intl. during the 4th quarter valued at about $99,000. Hedge funds and other institutional investors own 96.35% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: What are popular range trading strategies?

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.